Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CFO Dean L. Schorno bought 50,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were purchased at an average cost of $2.13 per share, for a total transaction of $106,500.00. Following the transaction, the chief financial officer now owns 46,726 shares in the company, valued at $99,526.38. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Rigel Pharmaceuticals stock opened at $2.14 on Friday. Rigel Pharmaceuticals, Inc. has a 52 week low of $1.96 and a 52 week high of $3.98. The company has a current ratio of 5.33, a quick ratio of 5.29 and a debt-to-equity ratio of 0.26. The company has a market cap of $357.79 million, a price-to-earnings ratio of -4.86 and a beta of 1.18.
Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. Rigel Pharmaceuticals had a negative net margin of 111.48% and a negative return on equity of 58.94%. The company had revenue of $12.62 million during the quarter, compared to analyst estimates of $12.00 million. During the same quarter last year, the business posted ($0.17) EPS. As a group, sell-side analysts expect that Rigel Pharmaceuticals, Inc. will post -0.31 earnings per share for the current fiscal year.
RIGL has been the topic of several recent analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $7.00 target price (down previously from $9.00) on shares of Rigel Pharmaceuticals in a research report on Thursday, February 28th. Zacks Investment Research raised shares of Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 1st. Finally, BidaskClub cut shares of Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $6.60.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/4353124/dean-l-schorno-acquires-50000-shares-of-rigel-pharmaceuticals-inc-rigl-stock.html.
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia.
Further Reading: What causes a recession?
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.